Literature DB >> 19738244

Health care cost growth among the privately insured.

M Kate Bundorf1, Anne Royalty, Laurence C Baker.   

Abstract

Controlling health care cost growth remains a high priority for policymakers and private decisionmakers, yet little is known about sources of this growth. We examined spending growth among the privately insured between 2001 and 2006, separating the contributions of price changes from those driven by consumption. Most spending growth was driven by outpatient services and pharmaceuticals, with growth in quantities explaining the entire growth in outpatient spending and about three-quarters of growth in spending on prescription drugs. Rising prices played a greater role in growth in spending for brand-name than for generic drugs. These findings can inform efforts to control private- sector spending.

Entities:  

Mesh:

Year:  2009        PMID: 19738244     DOI: 10.1377/hlthaff.28.5.1294

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  11 in total

1.  Growth hormone and health policy.

Authors:  Leona Cuttler; J B Silvers
Journal:  J Clin Endocrinol Metab       Date:  2010-04-28       Impact factor: 5.958

2.  Global study of primary immunodeficiency diseases (PI)--diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation.

Authors:  Vicki Modell; Bonnie Gee; David B Lewis; Jordan S Orange; Chaim M Roifman; John M Routes; Ricardo U Sorensen; Luigi D Notarangelo; Fred Modell
Journal:  Immunol Res       Date:  2011-10       Impact factor: 2.829

3.  Decomposing changes in the growth of U.S. prescription drug use and expenditures, 1999-2016.

Authors:  Thomas M Selden; Salam Abdus; G Edward Miller
Journal:  Health Serv Res       Date:  2019-05-09       Impact factor: 3.402

4.  Medical care price indexes for patients with employer-provided insurance: nationally representative estimates from MarketScan Data.

Authors:  Abe Dunn; Eli Liebman; Sarah Pack; Adam Hale Shapiro
Journal:  Health Serv Res       Date:  2012-10-22       Impact factor: 3.402

5.  Decomposition Analysis of Spending and Price Trends for Biologic Antirheumatic Drugs in Medicare and Medicaid.

Authors:  Natalie McCormick; Zachary S Wallace; Chana A Sacks; John Hsu; Hyon K Choi
Journal:  Arthritis Rheumatol       Date:  2020-01-06       Impact factor: 10.995

6.  Modeling strategy to identify patients with primary immunodeficiency utilizing risk management and outcome measurement.

Authors:  Vicki Modell; Jessica Quinn; Grant Ginsberg; Ron Gladue; Jordan Orange; Fred Modell
Journal:  Immunol Res       Date:  2017-06       Impact factor: 2.829

7.  The Evolution of Health Insurer Costs in Massachusetts, 2010-12.

Authors:  Kate Ho; Ariel Pakes; Mark Shepard
Journal:  Rev Ind Organ       Date:  2018-03-15

8.  Primary immunodeficiencies worldwide: an updated overview from the Jeffrey Modell Centers Global Network.

Authors:  Vicki Modell; Jessica Quinn; Jordan Orange; Luigi D Notarangelo; Fred Modell
Journal:  Immunol Res       Date:  2016-06       Impact factor: 2.829

9.  Growth in medicare expenditures for patients with acute myocardial infarction: a comparison of 1998 through 1999 and 2008.

Authors:  Donald S Likosky; Weiping Zhou; David J Malenka; William B Borden; Brahmajee K Nallamothu; Jonathan S Skinner
Journal:  JAMA Intern Med       Date:  2013 Dec 9-23       Impact factor: 21.873

10.  Global report on primary immunodeficiencies: 2018 update from the Jeffrey Modell Centers Network on disease classification, regional trends, treatment modalities, and physician reported outcomes.

Authors:  Vicki Modell; Jordan S Orange; Jessica Quinn; Fred Modell
Journal:  Immunol Res       Date:  2018-06       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.